Organization | Guangdong Zhaotai InVivo Biomedicine Co. Ltd.

Guangdong Zhaotai InVivo Biomedicine Co. Ltd. Report issue

Government Phase 1

Organization Overview

First Clinical Trial

2017

NCT03198546

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Guangdong Zhaotai InVivo Biomedicine Co. Ltd.

Active Ingredients

Drugs in Phase 1 Trials (3)

cpg-odn (1 trial)

gpc3 and/or tgfβ targeting car-t cells (1 trial)

tils and car-tils targeting her2, mesothelin, psca, muc1, lewis-y, gpc3, axl, egfr, claudin18.2/6, ror1, gd1, or b7-h3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma (Phase 1)

Carcinoma, Hepatocellular (Phase 1)

Overview

Highest Phase: Phase 1
# of Trials: 3
# of Trial APIs: 3